PHARMACOKINETICS AND EXPOSURE-RESPONSE OF TOFACITINIB IN A PHASE 3 MAINTENANCE STUDY IN ULCERATIVE COLITIS PATIENTS

被引：2
|
作者：
Mukherjee, Arnab
D'Haens, Geert R.
Sandborn, William J.
Tsuchiwata, Shinichi
Vong, Camille
Deng, Chenhui
Xie, Rujia
Hazra, Anasuya
Martin, Steven W.
Friedman, Gary
Niezychowski, Wojciech
Su, Chinyu
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)32133-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1917
引用
收藏
页码：S595 / S596
页数：2
相关论文
共 50 条
  • [41] Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies
    Mukherjee, A.
    Tsuchiwata, S.
    Deng, C.
    Vong, C.
    Xie, R.
    Martin, S. W.
    Yu, D.
    Woodworth, D.
    Niezychowski, W.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S73 - S74
  • [42] Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
    Sandborn, William J.
    Armuzzi, Alessandro
    Liguori, Giuseppina
    Irving, Peter M.
    Sharara, Ala, I
    Mundayat, Rajiv
    Lawendy, Nervin
    Woolcott, John C.
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (09) : 1338 - 1347
  • [43] Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
    Thakre, Neha
    Goebel, Aline
    Winzenborg, Insa
    Suleiman, Ahmed A.
    D'Cunha, Ronilda
    Mensing, Sven
    Liu, Wei
    Pang, Yinuo
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 847 - 857
  • [44] Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib
    Gilmore, R.
    Fernandes, R.
    Hartley, I.
    Arzivian, A.
    Leong, R.
    Andrew, B.
    Vasudevan, A.
    Greeve, T.
    Moore, G.
    Kim, S.
    Lightowler, D.
    Singh, A.
    Mahy, G.
    Mithanthaya, A.
    Venugpal, K.
    Han, S.
    Bryant, R.
    West, J.
    Segal, J.
    Christensen, B.
    Ding, N. J.
    An, Y. K.
    Begun, J.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1904 - I1904
  • [45] Tofacitinib for the induction and maintenance of medically resistant ulcerative colitis
    Weisshof, R.
    Golan, M. Aharoni
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S404 - S404
  • [46] A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis
    Dreesen, Erwin
    Kantasiripitak, Wannee
    Detrez, Iris
    Stefanovic, Sebastian
    Vermeire, Severine
    Ferrante, Marc
    Bouillon, Thomas
    Drobne, David
    Gils, Ann
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (04) : 570 - 580
  • [47] Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
    Panes, Julian
    Vermeire, Severine
    Lindsay, James O.
    Sands, Bruce E.
    Su, Chinyu
    Friedman, Gary
    Zhang, Haiying
    Yarlas, Aaron
    Bayliss, Martha
    Maher, Stephen
    Cappelleri, Joseph C.
    Bushmakin, Andrew G.
    Rubin, David T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (02): : 145 - 156
  • [48] Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
    Friedrich, Stuart
    Chua, Laiyi
    Adams, David H.
    Crandall, Wallace
    Zhang, Xin Cindy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 435 - 447
  • [49] Loss of Response to Tofacitinib in Ulcerative Colitis Maintenance: A Systematic Review and Meta-Analysis
    Taneja, Vikas
    Systrom, Hannah
    Walradt, Trent
    El-Dallal, Mohammed
    Feuerstein, Joseph D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S442 - S443
  • [50] Exposure-response relationship during vedolizumab induction therapy in adults with ulcerative colitis
    Rosario, M.
    French, J.
    Dirks, N.
    Milton, A.
    Fox, I.
    Gastonguay, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S270 - S271
12345